Most lasting MS treatments for children and teens today

Credibility

Interest

Share:2 min read

Key Takeaway

In children and teens with MS, the B-cell–targeting drug rituximab kept patients on treatment the longest, suggesting it may work better and be easier to stay on than older injectable medicines.

What They Found

The researchers looked at 383 people who got MS before age 18 and followed them for about 10 years to see how long they stayed on different treatments. They used “treatment persistence” — how long someone keeps taking a medicine — as a sign of how well it works and how easy it is to tolerate. Rituximab, a medicine that lowers certain immune cells called B cells, had the best persistence: more than half stayed on it for the whole study time. Other newer drugs like natalizumab, fingolimod, and dimethyl fumarate worked better than older injectables (shots or small injections) but not as long as rituximab. Older injectables had the shortest time patients stayed on them, with a median of about 18 months, compared with much longer times for the other medicines.

Who Should Care and Why

Children and teens with MS and their families should care because longer treatment persistence often means the medicine controls MS symptoms and has tolerable side effects, which can mean fewer relapses or hospital visits. Caregivers may worry about how often treatments are given or side effects; rituximab is given less often (like a big dose every few months) compared with daily pills or frequent injections, which some families find easier to manage. Doctors and nurses can use this information when talking about treatment plans, weighing whether a less frequent, highly effective option might fit a young person’s life better. If a young person struggles with daily pills or regular injections, a therapy that keeps people on treatment longer might improve school attendance and overall well-being, similar to switching from a difficult daily chore to a simpler monthly task. MS clinics, especially those treating children, may use these findings to consider B-cell therapies earlier when balancing benefits and risks.

Important Considerations

This study looks at registry data, so it shows patterns but cannot prove one drug causes better outcomes — other factors like how sick someone was or local treatment rules could affect results. Side effects and long-term safety, especially in kids, were not the main focus here, so families should still discuss risks like infection risk with B-cell therapies. The study was done in Sweden and included the medicines commonly used there, so results might differ in other countries or for patients with different medical histories.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Clinical Trials Treatment Updates Living with MS

Article Topics:

Disease-modifying therapieschildrencohort studyreal-world evidence

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Multiple sclerosis (Houndmills, Basingstoke, England) often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News